Document is current
Any future updates will be listed below
-
Authors
Jiang, Bin
Li, Jian
Liu, Ligen
Du, Xin
Jiang, Hao
Hu, Jianda
Zeng, Xiaoxi
Sakatani, Taishi
Kosako, Masanori https://orcid.org/0000-0002-4981-9450
Deng, Yaru
Girshova, Larisa
Bondarenko, Sergey
Lee, Lily Wong Lee
Khuhapinant, Archrob
Martynova, Elena
Hasabou, Nahla
Wang, Jianxiang
-
Funding
Funding for this research was provided by:
Astellas Pharma Inc.
- License Information
-
More Information
Article History
Received: 10 October 2024
Accepted: 27 January 2025
First Online: 10 March 2025
Declarations
:
: This trial was conducted in accordance with the study protocol, the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use guidelines and Declaration of Helsinki, and applicable regulations/guidelines governing clinical study conduct and ethical principles.
: Written and signed informed consent was obtained from all patients or their guardian or legal representative prior to screening. The study sponsor ensured that the use and disclosure of protected health information obtained during the trial complied with federal and/or regional legislation related to the privacy and protection of personal information.
: JW, BJ, JL, LL, XD, HJ, JD, LG, SB, LWLL and EM have nothing to disclose. TS reports Astellas stocks. AK reports consulting and honoraria fees from Roche, Johnson & Johnson, Novartis, American Taiwan Biopharm, AstraZeneca, Dr. Reddy, Bristol Myers Squibb, and Apexcella; support for attending meetings and/or travel from American Taiwan Biopharm. XZ, TS, MK, YD, and NH are all employees of Astellas.
